Advances in Breast Cancer Treatment: HER2, Triple-Negative, and Immunotherapy

Jump To Section

• Expertise in Breast Cancer Therapy
• Leadership in Early Drug Development
• International Training and Research
• Key Roles in Oncology Organizations
• Editorial Leadership in Cancer Journals
• Recognition and Publications
• Future of Breast Cancer Care

Expertise in Breast Cancer Therapy

Dr. Giuseppe Curigliano, MD, is a world-renowned expert in cancer treatment, with a specific focus on the development of new cancer drugs. His work encompasses the treatment of various breast cancer types, including HER2-negative and HER2-positive breast cancers, as well as the challenging triple-negative breast cancer. Dr. Curigliano's research also extends to both early-stage and metastatic breast cancer, exploring the significant advances in immunotherapy that are changing patient outcomes.

Dr. Anton Titov, MD, the interviewer, highlights that discussions with Dr. Curigliano cover the entire spectrum of modern oncology challenges.

Leadership in Early Drug Development

Dr. Giuseppe Curigliano, MD, holds a pivotal leadership role as the Director of New Drugs and Early Drug Development for Innovative Therapies at the European Institute of Oncology in Milan. This position involves spearheading clinical studies and research programs focused on Phase 0, Phase I, and early Phase II clinical trials. These trials are critical for testing the safety and efficacy of novel treatments in patients with metastatic breast cancer and other solid tumors, bringing new hope to the field.

He is also a Professor of Medical Oncology at the University of Milano, where he educates the next generation of oncologists.

International Training and Research

The foundation of Dr. Curigliano's expertise is built on extensive international training. He obtained his MD from the University of Rome and completed a Ph.D. in Medical Pathophysiology and Clinical Pharmacology at the University of Pisa. His global perspective was further shaped by a fellowship in oncology and clinical immunology at the South Carolina Medical School in Charleston and research tenures at the prestigious National Cancer Institute in Bethesda.

Dr. Giuseppe Curigliano, MD, also gained invaluable experience working at the Cancer Center at Columbia University in New York and as a visiting scientist at the Dana-Farber Cancer Center, affiliated with Harvard Medical School in Boston.

Key Roles in Oncology Organizations

Dr. Giuseppe Curigliano, MD, has served in numerous influential roles within international oncology bodies. He has been a member of the Scientific Advisory Council for both the International Breast Cancer Study Group and the Breast International Group. His expertise is recognized at the regulatory level, having been named an "Expert Clinical Assessor for Oncology" at the European Medicines Agency (EMA), which evaluates new medications for approval.

Within the European Society of Medical Oncology (ESMO), Dr. Curigliano is a member of the Breast Faculty, has served as Chair of the Guidelines Committee, and is a Council Member, helping to shape treatment standards across Europe.

Editorial Leadership in Cancer Journals

Dr. Curigliano plays a critical role in disseminating cutting-edge cancer research through his editorial work. He serves on the editorial boards of top-tier journals including the Journal of Clinical Oncology and the Annals of Oncology. His leadership extends to being Co-Editor in Chief of The Breast and Cancer Treatment Reviews, and Associate Editor of the European Journal of Cancer.

This editorial oversight ensures that significant clinical findings in breast cancer therapy and drug development reach the global medical community efficiently and accurately.

Recognition and Publications

The contributions of Dr. Giuseppe Curigliano, MD, to oncology have been honored with prestigious awards, including the first ESO Umberto Veronesi Award and a Fellowship of the European Academy of Cancer Sciences, both received in 2017. His profound impact on the field is quantified by an extensive publication record of over 480 peer-reviewed articles in international medical journals.

Dr. Curigliano is also a frequent invited speaker at major international conferences, where he shares insights on cancer research and treatment advancements with colleagues worldwide.

Future of Breast Cancer Care

The work of experts like Dr. Giuseppe Curigliano, MD, is fundamentally shaping the future of oncology. His focus on early drug development for innovative therapies promises more personalized and effective treatment options for patients with aggressive breast cancer subtypes. The integration of immunotherapy and targeted agents continues to be a major area of progress.

As Dr. Anton Titov, MD discusses with leading figures, this relentless pursuit of innovation in clinical trials is key to improving survival rates and quality of life for cancer patients globally.

Full Transcript

Dr. Anton Titov, MD: Hello from Milan! We are with Dr. Giuseppe Curigliano, who is a world-renowned expert in cancer treatment and new cancer drug development.

We are going to discuss today the advances in the treatment of different breast cancer types, like HER2 negative and positive breast cancers, triple-negative breast cancer, early and metastatic breast cancers.

We will also talk about advances in immunotherapy and the challenges of new drug development in cancer treatment.

Let me give you an overview of the professional career of Professor Giuseppe Curigliano.

Dr. Giuseppe Curigliano is a Director of New Drugs and Early Drug Development for Innovative Therapies at the European Institute of Oncology in Milan, Italy. He is a Professor of Medical Oncology at the University of Milano.

Dr. Giuseppe Curigliano leads clinical studies and research programs concerning the Phase 0, I, and early Phase II treatments in metastatic breast cancer and solid tumors.

Dr. Giuseppe Curigliano obtained his MD from the University of Rome in Italy. He completed his Ph.D. in Medical Pathophysiology and Clinical Pharmacology at the University of Pisa.

Dr. Giuseppe Curigliano did a fellowship in oncology and clinical immunology at South Carolina Medical School, Charleston, United States, and research at the National Cancer Institute in Bethesda, United States.

He also worked at the Cancer Center at Columbia University in New York. Dr. Giuseppe Curigliano was a visiting scientist at Dana Farber Cancer Center, Harvard Medical School in Boston.

Dr. Giuseppe Curigliano was also a Co-Director of the Division of Medical Oncology, European Institute of Oncology in Milan, Italy.

Dr. Giuseppe Curigliano has been a member of the Scientific Advisory Council of the International Breast Cancer Study Group and a member of the Scientific Advisory Council of the Breast International Group.

Dr. Giuseppe Curigliano was named "Expert Clinical Assessor for Oncology" at the European Medicines Agency. He was the editor of the Project START (State of the Art Oncology in Europe).

He is a member of the Breast Faculty of the European Society of Medical Oncology, where he served as the Chair of the Guidelines Committee and is a Council Member.

Dr. Giuseppe Curigliano is on the faculty of the European School of Oncology and the faculty of the St Gallen Early Breast Cancer Conference.

Dr. Curigliano is the co-founder and scientific secretary of the International Cardio-Oncology Society.

Dr. Giuseppe Curigliano is a member of the editorial boards of the highly cited international clinical oncology journals: Journal of Clinical Oncology in the US and Annals of Oncology in Europe.

He is also a co-Editor in Chief of The Breast, Co-Editor in Chief of Cancer Treatment Reviews, and Associate Editor of the European Journal of Cancer.

Dr. Giuseppe Curigliano was awarded the first ESO Umberto Veronesi Award in Vienna in 2017 and with the Fellowship of the European Academy of Cancer Sciences in Paris in 2017.

Dr. Giuseppe Curigliano has authored and co-authored over 480 peer-reviewed publications in international medical journals and presented numerous talks at international conferences on cancer research and treatment.

Dr. Giuseppe Curigliano, hello and welcome!